Medicalsystem BiotechnologyLtd
Market Cap
CN¥7.9b
Last Updated
2021/04/17 09:17 UTC
Data Sources
Company Financials
Executive Summary
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of medical diagnostic products in China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Fair value with mediocre balance sheet.
Share Price & News
How has Medicalsystem BiotechnologyLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 300439 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 300439's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-5.3%
300439
-0.2%
CN Biotechs
-0.8%
CN Market
1 Year Return
44.7%
300439
33.0%
CN Biotechs
25.0%
CN Market
Return vs Industry: 300439 exceeded the CN Biotechs industry which returned 32.5% over the past year.
Return vs Market: 300439 exceeded the CN Market which returned 24.7% over the past year.
Shareholder returns
| 300439 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.3% | -0.2% | -0.8% |
| 30 Day | 8.1% | 9.5% | -0.08% |
| 90 Day | 33.3% | 2.9% | -5.3% |
| 1 Year | 44.7%44.7% | 33.4%33.0% | 27.0%25.0% |
| 3 Year | 1.7%0.09% | 85.6%82.7% | 29.1%22.8% |
| 5 Year | -12.1%-14.0% | 74.7%71.4% | 30.5%21.7% |
Long-Term Price Volatility Vs. Market
How volatile is Medicalsystem BiotechnologyLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Medicalsystem BiotechnologyLtd undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 300439 (CN¥23.02) is trading below our estimate of fair value (CN¥153.59)
Significantly Below Fair Value: 300439 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 300439 is unprofitable, so we can't compare its PE Ratio to the CN Biotechs industry average.
PE vs Market: 300439 is unprofitable, so we can't compare its PE Ratio to the CN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 300439's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 300439 is good value based on its PB Ratio (4.9x) compared to the CN Biotechs industry average (6.4x).
Future Growth
How is Medicalsystem BiotechnologyLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
28.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicalsystem BiotechnologyLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Medicalsystem BiotechnologyLtd performed over the past 5 years?
-41.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300439 is currently unprofitable.
Growing Profit Margin: 300439 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 300439 is unprofitable, and losses have increased over the past 5 years at a rate of 41% per year.
Accelerating Growth: Unable to compare 300439's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300439 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.9%).
Return on Equity
High ROE: 300439 has a negative Return on Equity (-30.21%), as it is currently unprofitable.
Financial Health
How is Medicalsystem BiotechnologyLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 300439's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 300439's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥170.9M).
Debt to Equity History and Analysis
Debt Level: 300439's debt to equity ratio (60.7%) is considered high.
Reducing Debt: 300439's debt to equity ratio has increased from 1.3% to 60.7% over the past 5 years.
Debt Coverage: 300439's debt is well covered by operating cash flow (99.4%).
Interest Coverage: 300439 is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Dividend
What is Medicalsystem BiotechnologyLtd current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 300439's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 300439's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 300439's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 300439's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 300439 is not paying a notable dividend for the CN market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 300439's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Ji Hua Zou (41 yo)
no data
Tenure
Mr. Zou Ji Hua serves as General Manager of Medicalsystem Biotechnology Co., Ltd. Mr. Zou served as Production Department Deputy Director, Assistant to General Manager and Deputy General Manager at Medical...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.9%.
Top Shareholders
Company Information
Medicalsystem Biotechnology Co.,Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medicalsystem Biotechnology Co.,Ltd
- Ticker: 300439
- Exchange: SZSE
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥7.887b
- Shares outstanding: 383.00m
- Website: https://www.nb-medicalsystem.com
Number of Employees
Location
- Medicalsystem Biotechnology Co.,Ltd
- No. 299, Qiming South Road
- Yinzhou
- Ningbo
- Zhejiang Province
- China
Listings
Biography
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of medical diagnostic products in China. The company offers vitro diagnostic, biochemical, blood ce...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 09:17 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.